Pull to refresh
Logo
First KRAS degrader shows tumor responses with no dose-limiting toxicity

First KRAS degrader shows tumor responses with no dose-limiting toxicity

New Capabilities

PAQ Therapeutics' PT0253 shrank tumors in pancreatic and colorectal cancer, including in patients who had already failed a KRAS-targeted drug.

Overview

Updated 51 minutes ago

PAQ Therapeutics released the first human data for PT0253, a drug that destroys the mutant KRAS G12D protein rather than blocking it. Across 44 patients with advanced solid tumors, weekly infusions caused no dose-limiting toxicity at any dose from 10 to 750 milligrams, and tumors shrank in colorectal and pancreatic cancer.

The most telling result came from patients who had already failed a KRAS-targeted drug. Six of those 12 patients had disease control, a group that exists precisely because inhibitors leave the mutant protein in the cell and tumors route around the block.

In first-line pancreatic cancer, 6 of 7 assessable patients responded to PT0253 plus standard four-drug chemotherapy. The trial is small, company-run and has no comparison arm, and chemotherapy alone shrinks these tumors in many patients.

Why it matters

If destroying KRAS works where blocking it fails, pancreatic and colorectal cancers get a second route to the same target.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

44
Patients dosed in monotherapy escalation
Adults with KRAS G12D mutant solid tumors received weekly PT0253 at doses from 10 to 750 milligrams.
0
Dose-limiting toxicities across the full dose range
No dose-limiting toxicity was reported at any dose, and no PT0253-specific pre-treatment prophylaxis was required.
86%
Objective responses in assessable first-line pancreatic patients
Six of seven patients with at least two scans responded to PT0253 plus modified FOLFIRINOX.
50%
Disease control after prior KRAS-targeted therapy
Six of 12 patients whose disease had progressed on a prior KRAS-targeted drug achieved disease control.
3 of 6
Partial responses in refractory colorectal cancer
At doses of 120 milligrams and above, half of the refractory colorectal patients responded, including one who had progressed on a prior KRAS-targeted agent.
91%
Median relative dose intensity in combination
Patients received most of their planned PT0253 dose alongside 75 to 80 percent of planned chemotherapy doses.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

December 2024 November 2026

4 events Latest: 2 days ago
Tap a bar to jump to that date
  1. PAQ presents first clinical data at ENA 2026

    Latest Conference

    Late-breaking abstract 6LBA reports no dose-limiting toxicities from 10 to 750 milligrams and partial responses in colorectal, pancreatic and lung cancer.

  2. Data cutoff for the ENA presentation

    Data

    By this date, 44 patients had received monotherapy and 13 of 14 combination patients remained on treatment.

  3. FDA approves daraxonrasib for pancreatic cancer

    Regulatory

    The RAS inhibitor, sold as Rasonque, is cleared for metastatic pancreatic cancer after prior treatment, setting the comparison any new drug will face.

  4. PAQ opens Phase 1 trial of PT0253

    Trial start

    The open-label study enrolls adults with KRAS G12D mutated advanced solid tumors, with safety and dose-finding as the primary goals.

Scenarios

1

PAQ launches a randomized trial of PT0253 plus chemotherapy in first-line pancreatic cancer

Likely Resolves by End of 2027

Discussed by: PAQ Therapeutics, which said the combination findings support further investigation in first-line disease

The company called the combination data supportive of further study, and 13 of 14 patients were still on treatment at the cutoff. A randomized trial would test whether adding PT0253 to modified FOLFIRINOX improves progression-free survival over chemotherapy alone, something a single-arm company trial cannot show.

2

Astellas reports the first efficacy data for the competing KRAS G12D degrader ASP3082

Possible Resolves by Q2 2027

Discussed by: Industry trackers of KRAS G12D degraders in clinical development

ASP3082 is the only other KRAS G12D degrader in human trials. If Astellas reports response or durability data first, it becomes the benchmark PT0253 is measured against, and whichever program reaches a randomized trial first shapes how the class is judged.

3

Full peer-reviewed data confirms the response rates hold as enrollment grows

Uncertain Resolves by Q2 2027

Discussed by: Conference abstract reviewers and oncology trade press, which noted the efficacy claims rest on secondary endpoints

The ENA results were company-reported, not peer reviewed, and the pancreatic combination figure rests on seven patients. A full presentation or journal paper with more patients and longer follow-up would show whether the responses deepen and persist or shrink toward what chemotherapy alone delivers.

4

Expansion cohort produces a safety signal that pauses the program

Unlikely Resolves by End of 2027

Discussed by: No party has predicted this; it is the standard failure mode for a first-in-human oncology drug

The clean safety profile so far covers 44 patients at doses up to 750 milligrams, most of them with grade 1 or 2 treatment-related events. Combining a new mechanism with four-drug chemotherapy in sicker first-line patients is where unexpected toxicity usually appears.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2019-2021

Sotorasib cracks "undruggable" KRAS (2019-2021)

Amgen's sotorasib was the first drug to successfully target KRAS, a protein that had resisted drug discovery for four decades. It binds the G12C variant and locks the protein in its inactive state. The Food and Drug Administration approved it in May 2021 for previously treated KRAS G12C lung cancer.

Then

Patients who had run out of options responded, and the approval opened the KRAS field to dozens of competing programs.

Now

Responses typically lasted months rather than years, because tumors reactivate the signaling pathway. That resistance is the problem degraders were built to solve.

Why this matters now

PT0253's most striking result came from patients who had already progressed on a KRAS-targeted drug, the exact failure mode sotorasib exposed.

1998-2001

Imatinib proves targeted kinase inhibition (1998-2001)

Imatinib, sold as Gleevec, was the first small molecule designed to block the product of a specific cancer-causing mutation, the BCR-ABL fusion in chronic myeloid leukemia. It turned a fatal leukemia into a manageable condition for most patients.

Then

Approval in 2001 made targeted cancer therapy a commercial and scientific reality.

Now

Resistance appeared within a few years as leukemia cells acquired new mutations in the kinase domain, which is why later targeted drugs were judged on durability, not just response rate.

Why this matters now

The same pattern, a strong initial response followed by resistance, shapes how clinicians read PT0253's early numbers.

2019

First PROTAC degrader enters human testing (2019)

Arvinas dosed the first patient with ARV-110, a bifunctional molecule that flags a target protein for disposal rather than blocking it. It was the first targeted protein degrader to reach human trials.

Then

The trial established that engineered degraders could be given to patients safely; efficacy in prostate cancer was limited.

Now

Degradation moved from a chemistry curiosity to a clinical modality, with programs now aimed at kinases, transcription factors and mutant RAS.

Why this matters now

PT0253 is one of the first degraders aimed at a validated cancer driver, and one of only two KRAS G12D degraders in the clinic.

Sources

(7)